LGALS9 and acute myeloid leukemia: Moreover, overexpression of TIM-3/Gal-9 has been found in AML patients who failed chemotherapy, suggesting that targeting TIM-3/Gal-9 in combination with chemotherapy induction may be an alternative approach to increasing the complete remission rate of patients with AML (52, 82).